Trial
NCT01668173
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Novartis
Condition
Myeloproliferative Neoplasms
Intervention
AUY922
Why stopped
patient safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-23